Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.

MLA

Wichmann, Christian Werner, et al. “Preclinical Radiolabeling, in Vivo Biodistribution and Positron Emission Tomography of a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2.” Nuclear Medicine & Biology, vol. 122, July 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.nucmedbio.2023.108366.

APA

Wichmann, C. W., Burvenich, I. J. G., Guo, N., Rigopoulos, A., McDonald, A., Cao, D., O’Keefe, G. J., Gong, S. J., Gan, H. K., Scott, F. E., Pore, N., Coats, S., & Scott, A. M. (2023). Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2. Nuclear Medicine & Biology, 122, N.PAG. https://doi.org/10.1016/j.nucmedbio.2023.108366

Chicago

Wichmann, Christian Werner, Ingrid Julienne Georgette Burvenich, Nancy Guo, Angela Rigopoulos, Alexander McDonald, Diana Cao, Graeme Joseph O’Keefe, et al. 2023. “Preclinical Radiolabeling, in Vivo Biodistribution and Positron Emission Tomography of a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2.” Nuclear Medicine & Biology 122 (July): N.PAG. doi:10.1016/j.nucmedbio.2023.108366.